Cargando…
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and I...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974482/ https://www.ncbi.nlm.nih.gov/pubmed/32010143 http://dx.doi.org/10.3389/fimmu.2019.03096 |
_version_ | 1783490104940036096 |
---|---|
author | von Stebut, Esther Boehncke, Wolf-Henning Ghoreschi, Kamran Gori, Tommaso Kaya, Ziya Thaci, Diamant Schäffler, Andreas |
author_facet | von Stebut, Esther Boehncke, Wolf-Henning Ghoreschi, Kamran Gori, Tommaso Kaya, Ziya Thaci, Diamant Schäffler, Andreas |
author_sort | von Stebut, Esther |
collection | PubMed |
description | Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and IL-17F, which act on immune and non-immune cell types and strongly contribute to tissue inflammation. In psoriatic lesions, IL-17A, IL-17E, and IL-17F are involved in neutrophil accumulation, followed by the formation of epidermal micro abscesses. IL-17A together with other Th17 cytokines also upregulates the production of several chemokines that are implicated in psoriasis pathogenesis. IL17A-targeting antibodies show an impressive clinical efficacy in patients with psoriasis. Studies have reported an improvement of at least 75% as measured by the psoriasis area and severity index (PASI) in >80% of patients treated with anti-IL-17A therapy. Psoriasis skin manifestations, cardiovascular as well as metabolic disease in psoriasis appear to share pathogenic mechanisms evolving around IL-17A and its proinflammatory role. Thus, anti-IL-17A therapy not only improves skin manifestations of psoriasis, but also cardiovascular inflammation as well as metabolic factors and different domains of psoriatic arthritis (PsA) including peripheral arthritis, enthesitis, dactylitis, and axial involvement. This review summarizes the biological role of IL-17A, before reviewing currently available data on its role in the physiology and pathophysiology of the skin, as well as the cardiovascular and the metabolic system. In conclusion, clinical recommendations for patients with moderate to severe psoriasis based on the current available data are given. |
format | Online Article Text |
id | pubmed-6974482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69744822020-01-31 IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications von Stebut, Esther Boehncke, Wolf-Henning Ghoreschi, Kamran Gori, Tommaso Kaya, Ziya Thaci, Diamant Schäffler, Andreas Front Immunol Immunology Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and IL-17F, which act on immune and non-immune cell types and strongly contribute to tissue inflammation. In psoriatic lesions, IL-17A, IL-17E, and IL-17F are involved in neutrophil accumulation, followed by the formation of epidermal micro abscesses. IL-17A together with other Th17 cytokines also upregulates the production of several chemokines that are implicated in psoriasis pathogenesis. IL17A-targeting antibodies show an impressive clinical efficacy in patients with psoriasis. Studies have reported an improvement of at least 75% as measured by the psoriasis area and severity index (PASI) in >80% of patients treated with anti-IL-17A therapy. Psoriasis skin manifestations, cardiovascular as well as metabolic disease in psoriasis appear to share pathogenic mechanisms evolving around IL-17A and its proinflammatory role. Thus, anti-IL-17A therapy not only improves skin manifestations of psoriasis, but also cardiovascular inflammation as well as metabolic factors and different domains of psoriatic arthritis (PsA) including peripheral arthritis, enthesitis, dactylitis, and axial involvement. This review summarizes the biological role of IL-17A, before reviewing currently available data on its role in the physiology and pathophysiology of the skin, as well as the cardiovascular and the metabolic system. In conclusion, clinical recommendations for patients with moderate to severe psoriasis based on the current available data are given. Frontiers Media S.A. 2020-01-15 /pmc/articles/PMC6974482/ /pubmed/32010143 http://dx.doi.org/10.3389/fimmu.2019.03096 Text en Copyright © 2020 von Stebut, Boehncke, Ghoreschi, Gori, Kaya, Thaci and Schäffler. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology von Stebut, Esther Boehncke, Wolf-Henning Ghoreschi, Kamran Gori, Tommaso Kaya, Ziya Thaci, Diamant Schäffler, Andreas IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title | IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_full | IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_fullStr | IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_full_unstemmed | IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_short | IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
title_sort | il-17a in psoriasis and beyond: cardiovascular and metabolic implications |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974482/ https://www.ncbi.nlm.nih.gov/pubmed/32010143 http://dx.doi.org/10.3389/fimmu.2019.03096 |
work_keys_str_mv | AT vonstebutesther il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT boehnckewolfhenning il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT ghoreschikamran il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT goritommaso il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT kayaziya il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT thacidiamant il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications AT schafflerandreas il17ainpsoriasisandbeyondcardiovascularandmetabolicimplications |